About

Asimov operates in the synthetic biology field, providing a combination of engineered cells, genes, and software to assist in advanced genetic design. Their main products include cloud-based software that helps clients in the biopharmaceutical industry design, simulate, and optimize genetic systems, along with engineered GMP host cells for therapeutic uses. Asimov stands out from competitors by offering a unique guarantee on their high titer cell lines for monoclonal antibodies, promising '4 g/L or it's free,' which reduces risk for their clients. The company's goal is to enable biopharma companies to enhance their production of protein therapeutics and scalable viral vectors, ensuring high quality and performance through their specialized teams in synthetic biology and process development.

Simplify's Take

What believers are saying

• Growing demand for gene therapy boosts Asimov's stable cell line development services.
• Integration with The Foundry enhances Asimov's capabilities in genetic design innovation.
• Surge in private investments in synthetic biology favors Asimov's biopharmaceutical solutions.

What critics are saying

• Reliance on GMP plasmids and transfection reagents increases costs and supply chain risks.
• Competition from other synthetic biology firms could impact Asimov's market share.
• Rapid technological changes may require continuous adaptation and innovation from Asimov.

What makes Asimov unique

• Asimov integrates synthetic biology, computer-aided design, and machine learning for genetic design.
• The company offers a '4 g/L or it's free' promise for monoclonal antibodies.
• Asimov's LV Edge System provides scalable, low-cost lentiviral production without transient transfection.

Help us improve and share your feedback! Did you find this helpful?

YesNo